4 June 2024

Sino Biological Finalizes Acquisition with Signalchem Biotech

Straightening Global Presence and Expanding Product Portfolio

Sino Biological has successfully concluded its acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc. (“SCB” or “SignalChem”). Sino Biological has acquired 100% of SCB shares in a deal valued at $48M USD, inclusive of all assets, assumed indebtedness, and net of cash deposits.

SignalChem Biotech Inc. Is renowned for its specialized bioactive enzyme, including kinases, proteases, phosphatases, ubiquitin and epigenetic enzymes. Over the past two decades, SCB has established proprietary production and quality control platforms, setting industry standards for the development and production of high-quality bioactive enzyme proteins to support scientists from basic research through drug discovery and development. Now operating as a wholly-owned subsidiary of Sino Biological, SCB will bring exclusive expertise in enzyme production to the company’s existing technology platforms. For more information, please visit www.signalchem.com.

Sino Biological remains committed to maintaining the high standards of quality, reliability, and customer satisfaction throughout the integration process. Customers can expect continued access to the same high-quality products and services they have come to rely on, backed by the combined expertise and resources of Sino Biological and SignalChem Biotech.

For more details regarding the purchase method, please stay tuned on the most updated information.

Sino Biological Finalizes Acquisition with Signalchem Biotech

Related articles

Newsletter for researchers

We gladly support you by keeping you updated on our latest products and the developments around our services.

we Connect you
Need help? Contact our technical support